modelM02AA04

Diagram of M02AA04

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:Oxyphenbutazone
ATC code:M02AA04
route:oral
compartments:1
dosage:150mg
volume of distribution:0.16L
clearance:0.025L/hr/kg
other parameters in model implementation

Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID) in the pyrazolidinedione class, formerly used for the treatment of pain and inflammation in conditions like arthritis. Due to significant safety concerns, including serious adverse hematologic reactions, it is no longer approved or widely used in most countries.

Pharmacokinetics

Estimated pharmacokinetic parameters for healthy adults based on available references for structurally similar NSAIDs and limited legacy reports. No published detailed compartmental PK models found for oxyphenbutazone.

References

  1. Chay, S, et al., & Yocum, J (1984). Population distributions of phenylbutazone and oxyphenbutazone after oral and i.v. dosing in horses. Journal of veterinary pharmacology and therapeutics 7(4) 265–276. DOI:10.1111/j.1365-2885.1984.tb00911.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/6512917

  2. Brouwers, JR, & de Smet, PA (1994). Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clinical pharmacokinetics 27(6) 462–485. DOI:10.2165/00003088-199427060-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7882636

  3. Tobin, T, et al., & Lees, P (1986). Phenylbutazone in the horse: a review. Journal of veterinary pharmacology and therapeutics 9(1) 1–25. DOI:10.1111/j.1365-2885.1986.tb00008.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/3517382

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)